Efficacy of combined antipyretic drug in the treatment of acute respiratory diseases

Cover Page


Cite item

Full Text

Abstract

Aim. To evaluate efficacy of combined antipyretic drug in the treatment of acute respiratory diseases.

Methods. 97 children aged 3 to 6 years admitted in 2014-2015 were observed. Children were divided into 3 groups: in group 1 (23 children) paracetamol with single dose 10 to 15 mg/kg was administered, in group 2 (36 children) ibuprofen (single dose 6-10 mg/kg) was used, in group 3 (38 patients) combined antipyretic drug (100 mg of paracetamol and 125 mg of ibuprofen) was administered with daily dose not exceeding 3 tablets for less than 3 days. Clinical and instrumental and laboratory studies were performed in all children, specialists’ consultations were administered if necessary. Compliance (number of refusal to take medication because of inefficacy, intolerance of a drug or dissatisfaction with organoleptic properties of a drug) was assessed by parents’ surveys. Satisfaction with the results of treatment with a combined drug was evaluated by patients’ parents by means of integral scale IMPSS. Verification of certain etiologic factors was performed by means of direct immunofluorescence assay of nasal smear.

Results. As a result of the study it was found that among the etiologic factors of acute respiratory diseases of observed patients parainfluenza viruses and adenoviruses were predominant. When the combined drug was used, almost all parents were sure of children’s treatment safety. Administration of the combined drug was associated with faster and persistent fever reduction and decrease of children’s hospital stay. Due to long-term normal temperature when treated with combined drug children had better well-being, that positively influenced their sleep. In groups 1 and 2 with separately administered paracetamol and ibuprofen 28.3% of parents were unsatisfied with the medication while among the parents, whose children received a combination of ibuprofen and paracetamol, only 5.3% were unsatisfied (p <0.05 in comparison with groups 1 and 2).

Conclusion. Combined medication of ibuprofen and paracetamol approved itself to be safe and effective for fever reduction in children with acute respiratory diseases.

About the authors

O I Pikuza

Kazan state medical university

Email: azakirova@gmail.com
Kazan, Russia

R A Fayzullina

Kazan state medical university

Email: azakirova@gmail.com
Kazan, Russia

A M Zakirova

Kazan state medical university

Author for correspondence.
Email: azakirova@gmail.com
Kazan, Russia

Kh M Vakhitov

Kazan state medical university

Email: azakirova@gmail.com
Kazan, Russia

References

  1. Баранов А.А., Таточенко В.К., Бакрадзе М.Д. Лихорадочные синдромы у детей. Рекомендации по диагностике и лечению. М: Союз педиатров России. 2011; 228 с.
  2. Клинические рекомендации. Педиатрия. Под ред. А.А. Баранова. М.: ГЭОТАР-Медиа. 2009; 432 с.
  3. Ключников С.О., Барсукова М.В., Дубович Е.Г., Суюндукова А.С. Рациональные подходы к применению жаропонижающих препаратов у детей. МРЖ. 2010; (5): 243-247.
  4. Рык П.В., Царькова С.А. Проблемы выбора антипиретика в педиатрии. Consil. med. Педиатрия. 2010; (2): 72-77.
  5. Таточенко В.К., Бакрадзе М.Д. Лихорадка без видимого очага инфекции. Дет. инфекции. 2008; 6 (2): 56.
  6. Report of the Committee on infectious diseases. 27th ed. Elk Grove Village, III. American Academy of Pediatrics, 2006; 530.
  7. Тимченко В.Н., Павлова Е.Б. Современные подходы к терапии лихорадки у детей с инфекционной патологией. Педиатр. фармакол. 2008; 5 (5): 142-146.
  8. Webste R., Granoff A. Encyclopedia of virology. Academic Press. 1999; 2000 р.
  9. Клинические рекомендации для педиатров. Под ред. А.А. Баранова, В.К. Таточенко, М.Д. Бакрадзе. М.: Союз педиатров России. 2011; 228 с.
  10. Hay A., Costelloe C., Redmond N. et al. Paracetamol plus Ibuprofen for the treatment of fewer in children (PITCH). BMJ. 2008; 337: а 1302.

Supplementary files

Supplementary Files
Action
1. JATS XML

© 2017 Pikuza O.I., Fayzullina R.A., Zakirova A.M., Vakhitov K.M.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies